← Browse by Condition
Medical Condition
colorectal cancer crc
Total Trials
10
Recruiting Now
10
Trial Phases
Phase 2, Phase 1
NCT06640166 Phase 2
Recruiting
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
Enrollment
25 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
NCT06886282
Recruiting
Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease
Enrollment
80 pts
Location
Italy
Sponsor
National Cancer Institute, Nap...
NCT07047560 Phase 2
Recruiting
Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study
Enrollment
46 pts
Location
China
Sponsor
Tianjin Medical University Can...
NCT06751953
Recruiting
Neoantigen-loaded DC Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment
Enrollment
10 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT07349537 Phase 1
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Enrollment
574 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
NCT06751940
Recruiting
Neoantigen-loaded DC Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
Enrollment
10 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT06789172 Phase 1
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
Enrollment
166 pts
Location
United States, Austr...
Sponsor
Epkin
NCT06751914
Recruiting
Neoantigen-based Peptide Vaccine and Conventional Second-line Therapy for CRC Progressed After First-line Treatment
Enrollment
10 pts
Location
China
Sponsor
The First Affiliated Hospital ...
NCT07321106 Phase 1
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Enrollment
80 pts
Location
United States
Sponsor
Cartography Biosciences
NCT06809660
Recruiting
Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (PERMICA)
Enrollment
200 pts
Location
France
Sponsor
Poitiers University Hospital